In today’s session Baxter International Inc (BAX) recorded an unusually high (758) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious BAX decrease. With 758 contracts traded and 994 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: BAX161118P00046000 closed last at: $1.35 or 382.1% up. About 292,531 shares traded hands. Baxter International Inc (NYSE:BAX) has risen 8.02% since April 14, 2016 and is uptrending. It has outperformed by 3.33% the S&P500.
Baxter International Inc (NYSE:BAX) Ratings Coverage
Out of 11 analysts covering Baxter International (NYSE:BAX), 5 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 45% are positive. Baxter International has been the topic of 20 analyst reports since July 30, 2015 according to StockzIntelligence Inc. As per Thursday, April 14, the company rating was upgraded by Piper Jaffray. Credit Suisse reinitiated the shares of BAX in a report on Monday, August 10 with “Neutral” rating. Piper Jaffray initiated it with “Overweight” rating and $39 target price in Monday, November 16 report. The rating was maintained by Credit Suisse on Monday, April 25 with “Neutral”. The rating was reinitiated by JP Morgan on Monday, June 6 with “Neutral”. The stock of Baxter International Inc (NYSE:BAX) earned “Sector Perform” rating by RBC Capital Markets on Wednesday, February 3. The firm has “Neutral” rating given on Tuesday, September 22 by UBS. As per Wednesday, May 4, the company rating was initiated by Evercore. The firm has “Hold” rating given on Friday, July 31 by S&P Research. Barclays Capital initiated Baxter International Inc (NYSE:BAX) rating on Thursday, September 15. Barclays Capital has “Overweight” rating and $52 price target.
According to Zacks Investment Research, “Baxter engages in the worldwide development, manufacture and distribution of a diversified line of products, systems and services used primarily in the health-care field. The company’s products are used by hospitals, clinical and medical research laboratories, blood and dialysis centers, rehabilitation centers, nursing homes, doctors’ offices and by patients, at home, under physician supervision.”
Insitutional Activity: The institutional sentiment decreased to 0.68 in Q2 2016. Its down 0.33, from 1.01 in 2016Q1. The ratio dropped, as 75 funds sold all Baxter International Inc shares owned while 363 reduced positions. 67 funds bought stakes while 233 increased positions. They now own 437.24 million shares or 6.33% less from 466.81 million shares in 2016Q1.
Lazard Asset Mgmt Limited Liability Corp has 0.05% invested in the company for 501,264 shares. The California-based Analytic Investors Lc has invested 0.91% in Baxter International Inc (NYSE:BAX). Linscomb & Williams holds 0.16% or 35,788 shares in its portfolio. Louisiana State Employees Retirement Sys holds 36,200 shares or 0.09% of its portfolio. Piedmont Ltd Liability Corporation has 155,881 shares for 0% of their US portfolio. Howard Hughes Med Institute accumulated 0.11% or 7,389 shares. Baxter Bros has invested 0.08% of its portfolio in Baxter International Inc (NYSE:BAX). Lawson Kroeker Investment Management Ne, a Nebraska-based fund reported 5,100 shares. Plante Moran Financial Limited Liability last reported 1,035 shares in the company. Finemark Bancorp And Trust has 0.05% invested in the company for 9,274 shares. Brick & Kyle Associate accumulated 500 shares or 0.02% of the stock. Welch & Forbes Ltd Liability Corporation holds 0.02% of its portfolio in Baxter International Inc (NYSE:BAX) for 11,550 shares. Benjamin F Edwards Inc last reported 2,393 shares in the company. Yhb Inv, a Connecticut-based fund reported 5,558 shares. Lmr Ptnrs Llp accumulated 0.16% or 22,649 shares.
Insider Transactions: Since May 23, 2016, the stock had 1 insider buy, and 0 insider sales for $499,790 net activity. ALMEIDA JOSE E bought $499,790 worth of stock or 11,691 shares.
Baxter International Inc., through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The company has a market cap of $25.80 billion. The Firm operates through two divisions: Hospital Products and Renal. It has a 5.22 P/E ratio. The Company’s Hospital Products business makes IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products.
BAX Company Profile
Baxter International Inc., incorporated on October 19, 1931, through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The Firm operates through two divisions: Hospital Products and Renal. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision. The Firm makes products in approximately 30 countries and sells them in approximately 120 countries.
More recent Baxter International Inc (NYSE:BAX) news were published by: Fool.com which released: “Baxter International Inc Gets More Efficient” on October 26, 2016. Also Businesswire.com published the news titled: “Baxter Declares Quarterly Dividend and Announces Expanded Share Repurchase …” on November 08, 2016. Businesswire.com‘s news article titled: “Baxter’s Sigma Spectrum Infusion System Awarded â€œ2016 Best in KLASâ€ Among All …” with publication date: November 10, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.